Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
301060 Shanghai Labway Clinical Laboratory
22.900
+0.490+2.19%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Total operating revenue
143.91% 3.11B 167.17% 2.06B 132.24% 827.69M 43.62% 1.78B
Operating revenue
143.91% 3.11B 167.17% 2.06B 132.24% 827.69M 43.62% 1.78B
Total operating cost
117.79% 2.19B 126.06% 1.41B 97.21% 548.73M 37.60% 1.46B
Operating cost
126.05% 1.75B 129.76% 1.1B 97.19% 430.73M 31.02% 1.1B
Operating tax surcharges
-11.87% 3.39M -3.90% 2.23M 10.85% 1.15M 8.49% 4.93M
Operating expense
76.81% 136.54M 81.09% 96.49M 72.44% 41.56M 57.99% 125.48M
Administration expense
94.79% 245.71M 140.86% 184.59M 119.00% 62.51M 61.66% 193.63M
Financial expense
564.05% 5.23M 377.71% 1.53M 309.77% 276.85K 249.53% 1.05M
-Interest expense (Financial expense)
134.66% 5.56M 44.46% 2.32M 5.20% 755.22K -- 3.27M
-Interest Income (Financial expense)
-1.42% 1.89M -10.40% 1.32M -10.35% 684.57K 113.31% 2.69M
Research and development
110.16% 48.32M 107.76% 31.71M 106.19% 12.49M 80.91% 39.44M
Credit Impairment Loss
-176.42% -31.55M -88.33% -17.53M 21.85% -4.22M -15.11% -14.75M
Asset Impairment Loss
-95.22% -6.24M -48.38% -4.12M -1,234.52% -2.04M -51.60% -6.99M
Other net revenue
-4,589.90% -28.6M -619.03% -13.18M 258.28% 762.18K 3.41% 3.59M
Fair value change income
330.88% 1.66M -21.72% 1.66M -5.56% 1.66M 647.48% 3.93M
Invest income
-59.86% 2.11M -19.58% 2.64M 419.99% 1.84M -9.38% 6.24M
-Including: Investment income associates
-- -503.51K -- -- -- -- -- --
Asset deal income
-71.44% 244.58K -72.03% 133.28K -- 76.3K 58.85% 1.04M
Other revenue
-40.97% 5.17M -53.91% 4.03M 16.45% 3.44M 10.06% 14.13M
Operating profit
229.64% 892.73M 326.66% 634.09M 260.16% 279.73M 78.72% 318.95M
Add:Non operating Income
-93.35% 125.45K -59.11% 74.61K 8,305.05% 79.19K 249.50% 1.96M
Less:Non operating expense
689.92% 12.77M 696.79% 5.82M 933.90% 3.15M -82.83% 2.87M
Total profit
224.65% 880.08M 324.35% 628.34M 257.60% 276.65M 95.94% 318.03M
Less:Income tax cost
219.97% 147.16M 285.29% 101.63M 245.04% 45.5M 102.73% 56.41M
Net profit
225.61% 732.92M 332.82% 526.71M 260.18% 231.16M 94.54% 261.62M
Net profit from continuing operation
225.61% 732.92M 332.82% 526.71M 260.18% 231.16M 94.54% 261.62M
Less:Minority Profit
169.42% 128.6M 309.00% 96.16M 396.58% 53.92M 139.69% 57.78M
Net profit of parent company owners
240.73% 604.32M 338.53% 430.55M 232.41% 177.24M 84.68% 203.84M
Earning per share
Basic earning per share
199.84% 1.5088 285.86% 1.075 192.47% 0.4425 84.64% 0.5783
Diluted earning per share
199.84% 1.5088 285.86% 1.075 192.47% 0.4425 84.64% 0.5783
Other composite income
Total composite income
225.61% 732.92M 332.82% 526.71M 260.18% 231.16M 94.54% 261.62M
Total composite income of parent company owners
240.73% 604.32M 338.53% 430.55M 232.41% 177.24M 84.68% 203.84M
Total composite income of minority owners
169.42% 128.6M 309.00% 96.16M 396.58% 53.92M 139.69% 57.78M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
------Unqualified opinion
Auditor
------Rongcheng Accounting firm (Special General Partnership)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a high-tech enterprise that provides comprehensive health management solutions relying on medical laboratory and pathological diagnosis services. Through the business model of providing third-party medical diagnostic services and selling in vitro diagnostic products, the company enables medical technology laboratories such as hospital laboratory, pathology department and central laboratory to help them reduce operating costs and operational risks. improve the quality and technical level of medical services. At present, the company's business covers more than ten provinces and cities, and there are more than ten regional medical laboratory and pathological diagnosis centers, forming a brand, large-scale and standardized laboratory network. The company is an integrated service provider providing overall solutions for the inspection and diagnosis industry, providing third-party medical testing and pathological diagnosis services to medical institutions at all levels, selling in vitro diagnostic products of well-known brands at home and abroad and other professional technical support, in order to meet the differentiated needs of medical institutions at all levels. Medical laboratory and pathological diagnosis services, sales of in vitro diagnosis products, medical diagnosis services, etc. Corporate honors: top 100 Shanghai service enterprises in 2019, top 100 private service enterprises in Shanghai, civilized units in Shanghai, etc.
CEO: --
Market: --
Listing Date: 09/13/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist